Singapore, June 13 -- ZeroHarm Sciences, India's pioneering clean-label nutraceutical company, is embarking on an aggressive global expansion, targeting the United Kingdom and GCC markets, including the UAE and wider Middle East.
Riding a 10x revenue growth over the past two years and operating at a strong ~20% EBITDA margin, the startup aims to double its revenue by FY 2026. This move builds on its growing success in the United States, which now contributes nearly 30% of its total revenue.
At the heart of ZeroHarm's global success is its patented ZeroHarm BioEnhance platform, a pharma-grade nanotechnology that encapsulates plant-based actives at the nanoscale, dramatically enhancing their bioavailability by up to 5x, ensuring faster on...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.